Syndrome of Inappropriate Secretion of Antidiuretic Hormone in a Dog With Meningoencephalitis of Unknown Etiology. [PDF]
Vet Med SciThis report describes a case of syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a Maltese with meningoencephalitis of unknown etiology (MUE). The dog was treated with water restriction and tolvaptan, a vasopressin receptor antagonist, which resulted in an improvement in hyponatremia.
Lee Y +5 more
europepmc +2 more sources
Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series. [PDF]
CEN Case RepNishida J +3 more
europepmc +3 more sources
ESC Heart Failure, 2021 Aims Real‐world data on the use of tolvaptan, an oral selective vasopressin 2 receptor antagonist, for patients with heart failure (HF) are not available in Western countries because tolvaptan is not indicated in the Western countries for volume overload
Takashi Kuragaichi, Yukihito Sato
doaj +1 more source
Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan
Scientific Reports, 2021 Within no definite diuretic protocol for acute heart failure (AHF) patients and its variation in regional clinical guidelines, the latest national guidelines in Japan commends use of tolvaptan in diuretic-resistant patients.
Yusuke Yamazaki +6 more
doaj +1 more source
UNDULY ENHANCED RESPONSE TO TOLVAPTAN IN A WOMAN SHOWING SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: AN INVESTIGATION OF POSSIBLE CAUSES [PDF]
, 2017 Objective: To investigate possible causes of an excessive response to tolvaptan in a woman with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Lanzellotti, Davide +4 more
core +1 more source
Tolvaptan response predictors in acute heart failure patients with congestion [PDF]
Pharmaceutical Sciences Asia, 2022 Tolvaptan has been used in many countries as an adjunct to diuretic therapy for heart failure. The identification of predictors of response to tolvaptan is essential in developing individual treatment plans, and this study therefore aims to identify ...
Hindun Wilda Risni +2 more
doaj +1 more source
South Asian Journal of Cancer, 2014 AbstractHyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan.
Bharath Rangarajan +3 more
openaire +3 more sources
Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease [PDF]
, 2016 The neurohypophysial hormone arginine vasopressin (AVP) acts by three distinct receptor subtypes: V1a, V1b, and V2. In the liver, AVP is involved in ureogenesis, glycogenolysis, neoglucogenesis and regeneration. No data exist about the presence of AVP in
Alpini, Gianfranco +11 more
core +1 more source
Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
Kidney Diseases, 2021 Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide.
Fei Liu +4 more
doaj +1 more source
Tolvaptan induces body fluid loss and subsequent water conservation in normal rats
Journal of Pharmacological Sciences, 2022 We have recently reported that the urea osmolyte-associated water conservation system is activated in fluid loss models such as high salt-induced natriuresis, renal injury-induced impaired renal concentrating ability, or skin barrier dysfunction-induced ...
Satoshi Kidoguchi +6 more
doaj +1 more source